Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Spermosens AB is a Swedish medical technology company specializing in diagnostic products and services for male fertility health. Its primary purpose is to address male-factor infertility by offering innovative diagnostics and solutions tailored for fertility clinics, particularly within the IVF sector. Notably, Spermosens AB develops JUNO-Checked, a pioneering device engineered to measure the interaction between sperm and egg cells, enabling clinicians to select individualized fertility treatments based on precise biological data. Founded in 2018 and headquartered in Lund, the company operates with a small but specialized team and is recognized for its research and development in electromedical apparatus. Spermosens AB plays a niche but important role in the healthcare market, focusing on advancing reproductive medicine and improving outcomes for patients experiencing fertility challenges. Its offerings contribute to the broader landscape of assisted reproductive technology by enabling more personalized treatment approaches and addressing unmet diagnostic needs in male infertility.
kr 0.00
+kr 0.00 (+0.00%)
EOD Jun 26, 2026 · Twelve Data
Negative free cash flow of -kr 12M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
kr 0.00
Net Income (TTM)
-kr 9M
▲ +9.8% YoY
Op. Margin
—
ROIC
-24.23%
▲ +4.8pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-kr 9M
Op. Cash Flow (TTM)
-kr 7M
▼ -44.6% YoY
Net Debt
-kr 7M
Net Cash Position
Cash & Equiv.
kr 7M
Continue Research
Spermosens AB (SPERM.XSTO)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Spermosens AB scores 10/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Spermosens AB scores 10 out of 100 on Intrinsiqq's quality score, a weighted blend of 4 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -24.2% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh SPERM.XSTO's valuation and scores 10/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.